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Abstract
As an ever-progressing field of study, vaccine development has made headway over the past decades. By doing a comparative study 
between development of the measles vaccine in the mid-20th century, and the ongoing development of the COVID-19 vaccine in 
2020, many of the insights and advancements in the field can be easily highlighted. First, the knowledge and experience gained over 
those decades has helped the vaccine developing process become more efficient. With more vaccines in production, or at least under 
study, it is more likely to have a related precedent to build upon, as opposed to relying on a successful vaccine of some unrelated 
disease . More to the point, different vaccine types have altered the way researchers attempt to formulate future vaccines . No longer 
are inactivated and attenuated vaccines the only option; subunit vaccines, as well as innovative, (though yet to be proven), nucleic acid 
vaccines are now additional approaches. These advancements have opened doors for researchers in their quest to fight diseases. This 
paper will explore the advancements and their impact on the present-day COVID-19 vaccine development .
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Advancements in Vaccine Development:  
Measles vs. COVID-19
Though the majority of successful vaccines were devel-
oped in the 1900s, the challenge to develop vaccines still 
exists today, with both known diseases, such as cancer, 
as well as with novel infections that sweep the world. 
Measles used to be a common childhood disease; one 
which everyone contracted and with the majority of 
patients recovering completely. It was practically inevi-
table until the late 1900s, when a measles vaccine was 
introduced to the public. In the mid-1950s, after weeks of 
trying, John Enders’s lab successfully isolated the measles 
virus. Eventually, through implementation of routine mea-
sles vaccine—one dose at 12-15 months, and a second at 
4-6 years—measles was successfully eradicated from the 
U.S. in 2000, and from the Americas in 2016 (The College 
of Physician of Philadelphia, n.d.). However, that milestone 
of eliminating measles was not yet to be reached, as it was 
another ten years from the isolation of the virus until the 
measles vaccine officially debuted.
Contrastingly, it took Chinese researchers weeks to 
sequence the genome of SARS-CoV-2, a feat way beyond 
the simplicity of merely isolating the virus. Even more so, 
a projected release date for a safe and effective COVID-
19 vaccine is only 12-18 months from the start of devel-
opment, and one can only hope that the vaccine will erad-
icate the virus. Normally, vaccine development with FDA 
approval can take anywhere from 5-10 years. Obviously, 
vaccine technology has critically advanced in the decades 
since the measles vaccine, thus allowing researchers to 
expedite the vaccine development process for COVID-
19 and all future pandemics. This paper will explore some 
of these advancements and their potential impact on the 
COVID-19 vaccine development.
Methods
All of the information discussed in the paper was ob-
tained through the PubMed database, as well as via 
Google searches which led to government sites, like the 
CDC and NIH, and also to known and established med-
ical sciences related sites, like CHOP and The College of 
Physicians of Philadelphia.
The majority of the amassed information pertained to the 
techniques involved in developing both the measles vaccine 
and the potential COVID-19 vaccine, so that I could com-
pare and contrast the respective availability of resources.
One study explored in the paper included vaccine trial 
studies in which the efficacy of various measles vaccines 
were tested either alone, or in a series with other forms 
of developing measles vaccines. At a designated interval 
after each trial, measles titers were measured and even-
tually, the most effective vaccine was sought out.
There are currently over one hundred biotechnology 
companies and universities developing vaccine candidates 
for COVID-19. For the  vaccine studies that are not yet 
ready  for human test trials, i.e. majority of the COVID-19 
studies, this paper analyzed selected studies which elabo-
rated on the numerous approaches towards an effective 
COVID-19 vaccine.
Discussion 
An Overview of Vaccines 
How vaccines work
The purpose of a vaccine is to trigger the immune system 
to stimulate an initial immune response and ultimately 
create a cellular memory mechanism to fight future at-
tacks by the pathogen. This way, when the body is ex-
posed to the actual disease in the future, the body will 
produce an immediate secondary immune response and 
not a primary response (Clem, 2011). Secondary immune 
responses are quicker and more specific, and are there-
fore better than a primary immune response.
Classically, vaccines are created by deactivating or atten-
uating the virulent part of the pathogen, while leaving the 
antigenic portion of the pathogen intact so that the vac-
cine can induce an immune response without causing the 
disease itself  (The College of Physicians of Philadelphia, 
2018). When the body detects a foreign antigen, the innate 
immune system goes into action first (Clem, 2011). The 
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innate system includes non-specific white blood cells (i.e., 
macrophages and natural killer cells), which can either de-
stroy the invader or process the pathogen and present its 
antigen to aid in the adaptive immune response. Both the 
humoral and cell-mediated immune responses are part 
of the adaptive immune response. The humoral response 
consists of B-cells, which detect the foreign antigen and 
then self-mutate to find the antibody that best fits the 
antigen. After that is successfully accomplished, the B-cell 
that is able to produce the most effective neutralizing 
antibodies replicates and becomes either plasma cells, 
which secrete antibodies to help fight the current infec-
tion, or it creates memory B-cells specific to that antigen, 
so that upon future infection the body will have an anti-
body that targets and destroys the specific disease patho-
gens. The cell-mediated immune response contains two 
types of cells, T-killer and T-helper cells, which are either 
activated by major histocompatibility complex I (MHC I) 
or major histocompatibility complex II (MHC II). MHC 
proteins are expressed on the surface of all bodily cells 
to signal that the cells belong in the body. However, when 
the cells become infected with a pathogen the MHC will 
take the processed antigen and present it on the surface 
of the cell, so that the T cells of the cell-mediated immune 
system can respond. T-killer cells recognize the antigen 
presented by MHC I molecules and subsequently advance 
to kill the invading cell. On the other hand, T-helper cells 
recognize the antigen presented by MHC II molecules, 
and T-helper cells aid in the activation of B cells as well 
as T-killer cells. Regardless of their function, either T cell 
can replicate and form T-memory cells in preparation of 
future infections (Clem, 2011). In all, the job of a vaccine is 
to prime the body for a future encounter with a specific 
pathogenic agent.
Stages of Vaccine Production
Before any vaccine can be mass produced for public use, 
it must go through a series of developmental phases to 
assess first and foremost its safety, in addition to the vac-
cine’s efficacy, required dosage and dose frequency, and 
screenings for any harmful side effects (The College of 
Physicians of Philadelphia, 2018). Prior to these phases 
though, researchers study the specific disease and at-
tempt to identify its immunogenic parts. Once that has 
been done, researchers can either isolate the antigenic 
portion, or inactivate the virulent part, depending on 
what type of vaccine they propose to create.
Following those preliminary steps, the candidate vaccine 
can then enter the preclinical phase of study. In this stage, 
researchers test the vaccine safety and immunogenicity 
on animals (The College of Physicians of Philadelphia, 
2018). Also during this preclinical stage, researchers may 
conduct what are known as challenge trials. In these tests, 
researchers inject their candidate vaccine into the lab an-
imals or human volunteers, wait an amount of time so 
that the vaccine can elicit an immune response and create 
memory cells, and then finally, they inject the targeted 
virus into the subjects to determine if the vaccine can 
do its job. Based on the challenge trial results, research-
ers will adjust their vaccine development accordingly. 
During this phase, there may be a bit of trial and error 
in determining a safe starting dose, i.e. how many viral 
particles are needed to elicit an immune reaction, and 
method of delivery for human subjects of the next phase 
(The College of Physicians of Philadelphia, 2018). For the 
COVID-19 mRNA vaccine trials conducted by Moderna 
and the NIAID, three trial groups have been set up each 
with a different dosage. One group is testing the low 
dose of 25mcg, a second group is receiving the midrage 
amount of 100mcg, and the third group is receiving the 
highest dose, 250mcg (National Institute for Allergy and 
Infectious Disease [NIAID], 2020).
In order to advance from the preclinical stage to the 
clinical phases, the research group must submit an inves-
tigational new drug (IND) application to the FDA for ap-
proval to further their studies (The College of Physicians 
of Philadelphia, 2018). Once the researchers receive 
authorization, they can proceed to phase I clinical trials. 
At this juncture, researchers experiment with human 
subjects once again to test safety and immunogenicity 
of the proposed vaccine. This step starts with healthy 
adult subjects and if the vaccine is intended for younger 
or older age groups, the trials gradually trend towards 
the desired group. During this phase, researchers may 
conduct human challenge trials as well (The College of 
Physicians of Philadelphia, 2018). With regard to COVID-
19, Moderna has reported that after two doses of their 
potential mRNA COVID-19 vaccine, participants in the 
low and mid groups have expressed immunity at or above 
the level in which someone who was naturally infected 
would have. This seems to be a promising result for phase 
I trials, especially since it seems that once someone con-
tracts COVID-19 they do not get it again, and so the nat-
ural amount of antibodies should be sufficient for vaccine 
induced protection (CBS News, 2020).
After successful phase I trials, the vaccine can move on 
to phase II clinical trials. Here, researchers study a larger 
test group including a control group and the main point 
of this phase is to further characterize dosage, frequency 
of immunization, and method of delivery (The College of 
Physicians of Philadelphia, 2018). In this phase, the clinical 
studies will also ascertain whether the vaccine shows any 
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efficacy. Safety of the vaccine is monitored as well.
Next, there are phase III clinical trials. This is where 
the potential vaccine is determined to be effective by 
recruiting hundreds or thousands of volunteers to help 
quantitate how effective the vaccine is in a large cohort 
(The College of Physicians of Philadelphia, 2018). The 
large subject group also allows for the detection of rare 
side effects. During this phase, vaccine safety and dosage 
are still monitored for necessary corrections. Vaccines 
are never 100% effective. Measle vaccine is thought to be 
about 85% effective. Therefore, phase III trials must assess 
vaccine effectiveness. 
Finally, after the vaccine has successfully passed through 
all phases of clinical testing, the researchers can submit 
a biologics license application to the FDA for licensure 
of their candidate vaccine (The College of Physicians of 
Philadelphia, 2018). If the FDA approves, and the CDC 
subsequently recommends this vaccine for routine ad-
ministration, the researchers will be able to manufacture 
their vaccine and enable mass population immunization.
At this point, researchers can conduct an optional phase 
IV clinical trial to further monitor the vaccine’s safety and 
efficacy (The College of Physicians of Philadelphia, 2018). 
Studies can also be done to learn if the vaccine has poten-
tial for any alternate uses (i.e. other than for protection of 
the targeted pathogen).
Post licensure, the FDA and CDC continue to monitor 
the vaccine (The College of Physicians of Philadelphia, 
2018). In 1990, the FDA and CDC established the vac-
cine adverse event reporting system (VAERS). The VAERS 
allows for anyone to report adverse side effects, which 
seem to be caused by a particular vaccine. The CDC then 
analyzes all of the input data to determine several con-
clusions. Among those conclusions are whether a new 
adverse side effect has indeed been detected, and wheth-
er certain health conditions place a patient at a greater 
risk of developing an adverse side effect. Also in 1990, the 
CDC established the vaccine safety datalink (VSD). This 
system provides access to numerous databases listing 
which vaccines were given to a particular patient on the 
reported date. The VSD conducts vaccine safety studies 
based on questions raised in medical literature or reports 
from the VAERS. In addition, the VSD monitors the safety 
of new vaccines.
Advances in Vaccine Development
In the sixty years since the development of the measles 
vaccine, the technologies used have improved as well as 
increased. For example, while Enders, Hilleman, and all the 
other researchers of that time were experimenting with 
either inactivated (dead virus) or live-attenuated vaccines, 
researchers of today can work with a greater variety of 
vaccine types ranging from pathogen subunit vaccines 
to nucleic acid vaccines (NIAID, n.d.). Both forms of the 
newer vaccine methods aim at inoculating with only the 
antigenic portion of the microbe as opposed to injecting 
the whole pathogen, which is what is done with inactivat-
ed and attenuated vaccines. In an inactivated vaccine, the 
entire pathogen is killed and then subsequently adminis-
tered to the patient (Clem, 2011). Attenuated vaccines, on 
the other hand, leave the pathogen partially alive, and then 
upon administration, induce a stronger immune response 
than inactivated vaccines. However, because the attenuat-
ed vaccine is slightly live, it does present a greater risk to 
the immunocompromised community (Clem, 2011). The 
challenge in designing inactivated viruses or attenuated 
viral particles is that there is no set formula for how to 
kill or attenuate the virus. Each virus is different. That is 
why it can take months, or even years, to generate an 
effective candidate vaccine. 
Over the past decade, new innovative technologies 
have been instituted to develop effective vaccines. Subunit 
vaccines are one example where a mere pathogenic 
unit—a protein, or sugars on the microbe’s outer coat—
are administered into the patient to elicit an antibody re-
sponse, thus allowing a person to attain immunity (NIAID, 
n.d.). However, subunits vaccines are often not effective 
enough on their own and require an adjuvant to enhance 
their immune response (NIAID, n.d.). While historically 
composed of only aluminum salts, adjuvants today come 
in many more varieties like MF59 (oil in water emulsion 
composed of scalene), CpG 1018 (cytosine phosphogua-
nine, a synthetic form of DNA that mimics bacterial and 
viral genetic material), and others (Centers for Disease 
Control and Prevention [CDC], n.d.-a). All of these adju-
vants serve to aid in the immunogenicity of the vaccine, 
hopefully providing a stronger response and longer lasting 
protection. The inclusion of adjuvants in vaccine formula-
tion requires researchers to carefully assess where these 
added compounds elicit unwanted side effects. 
Contrary to the aforementioned vaccines, nucleic acid 
vaccines do not inject any physical part of the pathogen 
into the body. Rather, these vaccines inject a lab synthe-
sized DNA or mRNA sequence that codes for one or 
more antigenic proteins (NIAID, n.d.).  Once inside the 
body, the nucleic acid is taken up by the virally targeted 
cells and instructs those cells to synthesize and secrete 
the desired protein. Only then, after the protein is in the 
body, will the body generate an immune response and 
acquire antibodies to that specific disease (NIAID, n.d.). 
With this method of inoculation, the body itself is an in-
tegral part in creating the immunogenic portion of the 
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vaccine. An mRNA strand alone will do nothing. However, 
when acted upon in vivo, the body completes the last step 
in the vaccine synthesis, creating the protein to which it 
needs to attain immunity.
Nucleic acid vaccines have a quicker production time 
than traditional whole-pathogen vaccines (NIAID, n.d.). 
This is because a pathogenic specimen does not need to 
be grown for the creation of the vaccine (Park, 2020). 
Under normal circumstances, the microbe can take a few 
months to grow to the desired quantity. Thus, nucleic acid 
vaccines may be favored over whole-pathogen vaccines, 
especially in situations where time is a consideration.
Additionally, though nucleic acid vaccines can be inject-
ed directly into the body, another vaccine delivery mode 
has developed over the years. Instead of injecting the 
DNA or mRNA directly into the body, options now exist 
to use a vector for introduction of the vaccine (NIAID, 
n.d.). A vector is a small particle that acts as a vehicle for 
vaccine delivery. A viral vector, such as adeno-associated 
virus, can incorporate the vaccine’s genetic material by 
replacing some of its viral genes with the vaccine’s desired 
sequence (Robert-Guroff, 2007). Studies have proven 
that viral vector administration is both safe and effective, 
though the quantitative values vary amongst the viruses 
(Robert-Guroff, 2007). There are also non-viral vectors, 
for example, liposomes and lipid nanoparticles (LNP), 
which can be used to deliver nucleic acid vaccines as well. 
One advantage of non-viral vectors, is that they are less 
immunogenic than their viral counterparts. With both 
forms of vectors, however, the target site in the body can 
be specified with the help of specific receptor molecules. 
Like this, researchers can guide and control the vector’s 
integration and vaccine delivery within the body.
The Measles Vaccine
In 1954, just a year before the introduction of the in-
activated polio vaccine, Thomas Peebles, MD, working 
in John Enders’s lab at Boston Children’s Hospital, suc-
ceeded in isolating the measles virus from the blood of 
13-year-old David Edmonston (The College of Physicians 
of Philadelphia, n.d.). After isolating the virus, Enders’s goal 
was to formulate a vaccine. It took until 1960 to prove 
that the isolated strain could be formulated into an effec-
tive attenuated measles vaccine; it just needed addition-
al tweaking to attenuate it further (Hendriks & Blume, 
2013). Wanting other researchers to also attempt to 
create a measles vaccine, Enders shared the Edmonston 
strain. Most researchers of that time were inspired by the 
recent success of the polio vaccine, and tried to mimic 
that development in their construction of a measles vac-
cine (Hendriks & Blume, 2013). In countries where Salk’s 
inactivated polio vaccine (IPV) took credit for controlling 
the disease, like in Sweden and Netherlands, researchers 
worked at creating an effective inactivated measles vac-
cine. In other countries, such as the U.S. and U.K., where 
Sabin’s recently released oral polio vaccine (OPV) was 
used to combat polio, researchers preferred to attempt 
an attenuated version of the measles vaccine.
Regardless of the method chosen, subsequent patient 
trials proved the attenuated measles vaccine to be more 
effective than the inactive vaccine (Hendriks & Blume, 
2013). Some studies created several groups, each receiving 
a different vaccine regimen. While one group received only 
inactivated doses, another group received some inactive 
doses followed by a live dose, while  a third group received 
one dose of the attenuated vaccine. Though several studies 
tried this method, all pointed to the same results: the in-
activated vaccine initiated a lesser immune response and it 
was not known how long those antibody titers would last. 
The attenuated vaccine however, generated a substantial 
response, making it the vaccine of choice for elimination of 
measles (Hendriks & Blume, 2013).
It was in 1963 that John Enders and his associates re-
ceived FDA licensure for their live-attenuated measles 
vaccine and mass measles vaccination began (CDC, n.d.-b). 
However, the vaccine was not attenuated enough and thus 
required coadministration of gamma globulins to prevent 
children from developing fever and a rash following inocu-
lation (Hendriks & Blume, 2013). Approximately five years 
later, in 1968, Maurice Hilleman, working at Merck labs, 
developed Moraten—more attenuated Enders—which 
eliminated the need to inject the vaccine along with 
gamma globulins (Hendriks & Blume, 2013). Since licen-
sure, Moraten, a descendant of the original Edmonston 
strain, has been the only measles vaccine administered in 
the U.S. (The College of Physicians of Philadelphia, n.d.). 
Even today, when the monovalent vaccine is no longer on 
the market, the Edmonston strain is still used to create 
the measles component of the MMR vaccine routinely 
given to children (CDC, n.d.-c; The College of Physicians 
of Philadelphia, n.d.).
Potential COVID-19 Vaccines
The COVID-19 pandemic, rampant now in early 2020, and 
possibly beyond, has killed hundreds of thousands world-
wide in a matter of months (World Health Organization 
[WHO], 2020a). As of June 1, 2020, the WHO reports 
that there have been 371,166 deaths globally. Researchers 
all over the world are racing to develop a vaccine to com-
bat the virus and stop the ever-rising death toll.
Luckily, there is an extensive history of vaccine devel-
opment, allowing researchers to base their COVID-19 
77
Advancements in Vaccine Development: Measles vs. COVID-19
vaccine developments on the experiences and accu-
mulated information from the past. More so, unlike the 
measles vaccine development, COVID-19 vaccine devel-
opment has a related precedent. Coronaviruses SARS 
(severe acute respiratory syndrome) and MERS (Middle 
East respiratory syndrome), while claiming no marketed 
vaccine, have documented research and experimentation 
on vaccine development. Current researchers are using 
these semi-constructed vaccines and adapting them for 
further development towards the current strain of coro-
navirus, SARS-CoV-2. However, regardless of the starting 
inspiration, all potential COVID-19 vaccines will have to 
go through all phases of vaccine production before being 
offered on the market.
As of June 15, 2020, there are scores of COVID-19 
vaccine candidates starting the preclinical stage or clinical 
studies phase of vaccine development. These attempts 
include vaccine designs containing mRNA, DNA plasmid, 
protein subunit, non-replicating viral vectors, or inacti-
vated COVID-19 viral particles (WHO, 2020b). Just the 
breadth of these alone shows how many more resourc-
es and technologies are available now versus the 1960s, 
when the measles vaccine was in development.
The more recent vaccine technologies, namely nucleic 
acid vaccines, demonstrates  how the updated and in-
creased methods are truly playing a role in COVID-19 
vaccine development. In this paper, I would like to high-
light one specific mRNA candidate vaccine. (An LNP-
encapsulated mRNA vaccine, co-developed by Moderna 
and the NIAID.) As an RNA virus with RNA-dependent 
RNA polymerase, SARS-CoV-2 replicates RNA from an 
RNA template as opposed to transcribing RNA from 
a DNA template (using DNA-dependent RNA poly-
merase). This can result in high levels of RNA present 
within the virus (Wang, et al., 2020). Thus, using RNA 
as a method of priming the body towards an RNA-rich 
pathogen makes sense in the overall picture of vaccine 
development (Wang, et al., 2020).
Also, when developing this RNA vaccine, researchers 
opted to use the spike protein as the vaccine’s target 
sequence. Though there are other targetable proteins 
on SARS-CoV-2, such as the envelope, nucleocapsid, and 
membrane proteins, the spike (S) protein is the subunit 
of the virus that binds with the body’s ACE2 (angioten-
sin converting enzyme 2) receptor, and therefore the S 
protein comes across as a more effective vaccine target 
(Wang, et al., 2020; Zhang, et al., 2020). Figure 1 shows 
the location of all four proteins on the virus as well as the 
binding of the spike protein to the ACE2 receptor.
After injection of the vaccine which contains the mRNA 
sequence for the S protein, a cell in the body should 
translate the genetic code into the functional S protein that 
can be secreted to allow the immune system to respond. 
Figure 2 depicts the process by which this COVID-19 
mRNA vaccine ultimately yields memory cells in the body.
As of May 30, 2020, this candidate vaccine has advanced 
to phase 2 clinical trials (WHO, 2020b). Though mRNA 
vaccines have great theoretical potential, there are current-
ly none on the market. However, this mRNA vaccine may 
successfully proceed through all phases of vaccine develop-
ment, and should that happen, the Moderna/NIAID mRNA 
vaccine will be the first of its kind on the market
Conclusion
For the ongoing developments for a COVID-19 vaccine, 
it is unknown whether the vaccine’s immunity will be life-
long. Currently, it is unknown if natural immunity is long 
Figure 1 Proteins and Binding Site of SARS-CoV-2 Source . Zhang, et al ., 2020
Figure 2 COVID-19 mRNA Vaccine Response
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lasting, though whatever that case is, I would hypothesize 
that the artificially induced immunity would follow suit. In 
my opinion, though vaccine type does play a role in dura-
tion of immunity (as illustrated in measles vaccine devel-
opment), a larger portion depends upon the properties 
of the virus itself. Since that is yet to be determined, it 
is too soon to draw a conclusion with regards to any 
COVID-19 vaccine. Also, because all vaccines are at most 
in early phase II clinical trials, one cannot determine 
which candidate vaccine will be more effective than the 
others. Currently, the mRNA vaccine from Moderna is on 
a road to success, though results are still too incipient to 
make a final decision.
Finally, although the essence of a vaccine is unchanged—
the goal to elicit an effective immune response still drives 
development—advancements in vaccines development 
as well as accumulation of scientific knowledge have 
broadened our minds when attempting to develop a new 
vaccine. We now have more options, some of them with 
more precise targeting than ever, and it is the hope that 
with our newfound tools, we can go on to create better 
vaccines and continue saving lives.
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